Dopamine D2 receptor binding is reduced in Wilson's disease: Correlation of neurological deficits with striatal123I-Iodobenzamide binding
| Autor: | J. Spatt, Thomas Brücke, Lueder Deecke, W. Oder, Susanne Asenbaum, H. Kollegger |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male medicine.medical_specialty Pyrrolidines Neurology Central nervous system Striatum Iodine Radioisotopes Radioligand Assay chemistry.chemical_compound Iodobenzamide Hepatolenticular Degeneration Dopamine Internal medicine Dopamine receptor D2 Basal ganglia medicine Humans Biological Psychiatry Aged Tomography Emission-Computed Single-Photon Receptors Dopamine D2 business.industry Middle Aged medicine.disease Corpus Striatum Wilson's disease Psychiatry and Mental health medicine.anatomical_structure Endocrinology chemistry Case-Control Studies Benzamides Female Neurology (clinical) business medicine.drug |
| Zdroj: | Journal of Neural Transmission. 103:1093-1103 |
| ISSN: | 1435-1463 0300-9564 |
| DOI: | 10.1007/bf01291794 |
| Popis: | To visualise and quantify dopamine D2 receptor binding in the corpus striatum of patients with neurological Wilson's disease (WD) 123I-Iodobenzamide (IBZM) binding was measured using single photon emission computer tomography (SPECT). Ratios of striatal to frontal countrates were calculated in 8 patients and in 21 healthy control subjects. We found reduced IBZM binding ratios in all patients with WD in comparison to those in controls (1.48 +- 0.13 vs. 1.73 +- 0.09). The reduction in IBZM binding was correlated with the overall severity of neurological deficits and the severity of dysarthria (correlation coefficients −0.86 [p < 0.01] and −0.79 [p s< 0.01], respectively). When patients of three different subgroups of neurological WD were compared no differences in IBZM binding were found. We conclude that assessing basal ganglia function in vivo using IBZM-SPECT is a valuable diagnostic tool in WD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink